Guillaume Poliquin
Dr. Guillaume Poliquin is a Canadian researcher based in Winnipeg, Manitoba. He is notable during the COVID-19 pandemic due to his role at the National Microbiology Laboratory and on the National Advisory Committee on Immunization (NACI).
Career and Affiliations
University of Manitoba
Poliquin is employed at the University of Manitoba in the Department of Pediatrics and Child Health.1)
Public Health Agency of Canada
Poliquin is the Acting Vice-President of the National Microbiology Laboratory under the Public Health Agency of Canada.2) In this role, he is a liaison representative on the National Advisory Committee on Immunization (NACI), responsible for approving COVID-19 vaccines in Canada.3)
Canadian Immunization Research Network
Poliquin is a co-investigator with the Canadian Immunization Research Network (CIRN).4) The CIRN is funded by GlaxoSmithKline, Pfizer, Sanofi, and VBI Vaccines.5)
Research
Poliquin has conducted research in collaboration with VIDO-InterVac.6)
He also co-authored research funded by the National Institute of Allergy and Infectious Diseases (NIAID).7)
Links to Sort
1)
Funk, D. J., Bullard, J., Lother, S., Grande, G. V., Garnett, L., Doan, K., Dust, K., Kumar, A., Poliquin, G., & Strong, J. (2022). Persistence of live virus in critically ill patients infected with SARS-COV-2: a prospective observational study. Critical Care, 26(1). https://doi.org/10.1186/s13054-021-03884-z
2)
Dr. Guillaume Poliquin (Acting Vice-President, National Microbiology Laboratory, Public Health Agency of Canada) at the Canada-China Relations Committee. Open Parliament. Retrieved April 22, 2022, from https://openparliament.ca/committees/canada-china-relations/43-2/29/dr-guillaume-poliquin-1/only/
3)
National Advisory Committee on Immunization (NACI): Membership and representation. (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html
4)
Researchers. (2013, January 30). CIRN | Canadian Immunization Research Network. https://cirnetwork.ca/about-us/researchers/
5)
Partners. (2013, January 30). CIRN | Canadian Immunization Research Network. https://archive.ph/durb0
6)
Griffin, B. D., Chan, M., Tailor, N., Mendoza, E. J., Leung, A., Warner, B. M., Duggan, A. T., Moffat, E., He, S., Garnett, L., Tran, K. N., Banadyga, L., Albietz, A., Tierney, K., Audet, J., Bello, A., Vendramelli, R., Boese, A. S., Fernando, L., & Lindsay, L. R. (2021). SARS-CoV-2 infection and transmission in the North American deer mouse. Nature Communications, 12(1), 3612. https://doi.org/10.1038/s41467-021-23848-9
7)
Ranadheera, C., Valcourt, E. J., Warner, B. M., Poliquin, G., Rosenke, K., Frost, K., Tierney, K., Saturday, G., Miao, J., Westover, J. B., Gowen, B. B., Booth, S., Feldmann, H., Wang, Z., & Safronetz, D. (2020). Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-69054-3
8)
Chong, J., Quach, C., Blanchard, A. C., Poliquin, P. G., Golding, G. R., Laferrière, C., & Lévesque, S. (2016). Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit. Antimicrobial Agents and Chemotherapy, 60(10), 5673–5681. https://doi.org/10.1128/aac.00726-16